Foretinib (GSK1363089): Multikinase Inhibitor for Tumor Growth Control

Executive Summary: Foretinib (GSK1363089), supplied by APExBIO, is a highly potent ATP-competitive inhibitor targeting Met, VEGFR2, and several other receptor tyrosine kinases, with IC50 values in the low nanomolar range. Its anti-proliferative and anti-metastatic activity has been validated in a spectrum of in vitro and in vivo cancer models, including ovarian, melanoma, and prostate cancer. Foretinib induces G2/M cell cycle arrest, inhibits HGF-induced cell motility, and significantly reduces tumor burden in xenograft models. The compound’s robust benchmark data enable precise, reproducible integration into cancer research pipelines (Schwartz 2022).

Biological Rationale

Aberrant activation of receptor tyrosine kinases (RTKs) such as MET and VEGFR2 drives tumor proliferation, angiogenesis, and metastasis in multiple cancer types. These pathways are critical for tumor cell survival and migration, making them validated targets for therapeutic intervention (Schwartz 2022). Multikinase inhibitors expand the therapeutic window by simultaneously modulating several pro-tumorigenic signaling axes, reducing compensatory escape mechanisms seen with single-target agents. Foretinib’s broad inhibitory profile addresses the redundancy in RTK signaling networks, providing a rationale for its application in advanced cancer research.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive small molecule inhibitor with high affinity for multiple RTKs, including:

• MET (Hepatocyte Growth Factor Receptor): IC50 = 0.4 nM
• KDR (VEGFR2): IC50 = 0.9 nM
• Tie-2: IC50 = 1.1 nM
• VEGFR3/FLT4: IC50 = 2.8 nM
• RON: IC50 = 3 nM
• Other kinases (e.g., Flt-1, Flt-4, KIT, Flt-3, PDGFRα/β): low nanomolar IC50s

Foretinib’s blockade of MET and VEGFR signaling inhibits HGF-induced motility and angiogenesis, key drivers of tumor invasion and metastatic spread. In cancer cell lines, Foretinib induces G2/M cell cycle arrest and reduces proliferation, migration, and invasion, as seen in B16F10 melanoma, PC-3 prostate, A549 lung, HT29 colon, SK-HEP1 liver, SKOV3ip1 and HeyA8 ovarian cancer cells (APExBIO product information). In vivo, oral Foretinib at 30 mg/kg reduces tumor growth and metastasis in xenograft models.

Evidence & Benchmarks

• Foretinib inhibits MET kinase activity with an IC50 of 0.4 nM in enzyme assays (APExBIO product information).
• In cell-based assays, Foretinib blocks HGF-induced motility and proliferation at 0.25–1.5 μM, with maximum inhibition at ~1 μM after 48h (Schwartz 2022).
• Oral administration (30 mg/kg) reduces tumor volume and metastatic foci in murine xenograft models (Schwartz 2022).
• Foretinib is highly soluble in DMSO (≥31.65 mg/mL), but insoluble in water and ethanol (APExBIO product information).
• Compound stability: solid stored at -20°C is stable for months; solutions at -20°C are stable for several months when protected from light (APExBIO product information).

Compared to other multikinase inhibitors, Foretinib’s sub-nanomolar potency and broad target spectrum enable deeper suppression of RTK-driven pathways. For a mechanistic deep-dive on Foretinib’s selectivity and strategic integration in translational models, see this review, which is extended here with updated evidence benchmarks and workflow parameters.

Foretinib’s role in advanced cancer metastasis models is also discussed in this article, which our current analysis expands by offering quantitative protocol guidance and clarifying limitations.

Applications, Limits & Misconceptions

Foretinib is used extensively in:

• Tumor cell growth inhibition assays across multiple lineages (melanoma, prostate, ovarian, colon, lung, liver)
• Cell motility inhibition assays and migration/invasion studies
• In vivo cancer metastasis models, particularly xenograft systems
• Dissecting RTK crosstalk and resistance mechanisms in translational oncology

However, Foretinib is not intended for diagnostic or therapeutic use in humans or animals, and its activity in non-cancerous systems is poorly characterized (APExBIO product information).

Common Pitfalls or Misconceptions

• Foretinib’s solubility profile limits its use to DMSO-based formulations; attempts to dissolve in water or ethanol will fail.
• Working concentrations above 1.5 μM may not yield incremental biological benefit and can introduce off-target effects.
• Foretinib’s broad kinase inhibition can complicate interpretation in pathway-specific assays unless appropriate controls are included.
• Not suitable for direct clinical use or in vivo studies without appropriate ethical clearance and formulation optimization.
• Cell line-specific responses may vary; benchmarking in the intended cell background is essential (Schwartz 2022).

Workflow Integration & Parameters

Protocol Parameters

• Compound dissolution: Dissolve Foretinib at ≥31.65 mg/mL in DMSO; vortex thoroughly to ensure complete solubilization (APExBIO product information).
• Stock storage: Store solid at -20°C; DMSO stocks at -20°C protected from light are stable for several months.
• Working concentration: Use 0.25–1.5 μM for cell-based assays; maximal inhibition typically at 1 μM after 48 hours (Schwartz 2022).
• Medium compatibility: Add DMSO-dissolved Foretinib to culture medium; do not exceed 0.1% DMSO final concentration to minimize solvent toxicity.
• In vivo dosing: For murine xenograft models, 30 mg/kg oral administration has shown robust tumor reduction (Schwartz 2022).

For additional troubleshooting and advanced in vitro/in vivo protocols, see the in-depth guide at this resource; the present article updates those procedures with recent potency and solubility data.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated research tool for dissecting multikinase-driven cancer biology. Its low nanomolar potency, well-characterized mechanism, and reproducible benchmarks support its ongoing integration into functional and translational oncology workflows. The robust data on tumor growth inhibition, cell motility suppression, and metastasis control offer actionable metrics for drug discovery pipelines. Future research should further refine model-specific dosing and explore combinatorial regimens, leveraging the evidence base outlined here (Schwartz 2022).